A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
about
Safety of apixaban for venous thromboembolism prophylaxis: the evidence to dateNew oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic eventsPopulation Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure-Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism.Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillationLaboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review.Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis.A Systems Pharmacology Model for Predicting Effects of Factor Xa Inhibitors in Healthy Subjects: Assessment of Pharmacokinetics and Binding Kinetics.Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors.Incomplete Resolution of Deep Vein Thromboses during Rivaroxaban Therapy.Evaluation of the Antithrombotic Effects of Rivaroxaban and Apixaban Using the Total Thrombus-Formation Analysis System®: In Vitro and Ex Vivo Studies.Apixaban Concentration with and without Coadministration of Carbamazepine: A Case with No Apparent Interaction.Influence of Direct Oral Anticoagulants on Anti-Factor Xa Measurements Utilized for Monitoring Heparin.
P2860
Q26764874-46D7E3C6-36F8-4DB0-B981-FB4A399BE19FQ28080616-B1941B5A-C860-4A5A-85B0-885AA46242BDQ33729811-C64A2C66-83EF-4FB1-B1E2-7CF4E496C3AFQ36594607-6731F45D-5448-428E-BF98-646AA4F767B1Q38956699-A685BC11-6D90-4589-9498-7183E719A722Q39002657-F639C283-1135-4DDB-A097-F8F7CFDB5A07Q40090376-26621A44-E143-48F2-BDC5-5973EACC7742Q40705935-1EE0DEBA-0733-4118-A5BF-CCD13100C64BQ41371320-B30D8B5A-2156-4740-B5EA-D1862C93E213Q41627248-78C4916A-8A7C-45B9-9382-1B1622037DAFQ49335499-9A4D9290-545E-4FF8-BC51-445AFF36D9D1Q50237696-75392625-C72F-4B28-BA18-6A29E97AE4F3
P2860
A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A randomized direct comparison ...... cs of apixaban and rivaroxaban
@ast
A randomized direct comparison ...... cs of apixaban and rivaroxaban
@en
A randomized direct comparison ...... cs of apixaban and rivaroxaban
@nl
type
label
A randomized direct comparison ...... cs of apixaban and rivaroxaban
@ast
A randomized direct comparison ...... cs of apixaban and rivaroxaban
@en
A randomized direct comparison ...... cs of apixaban and rivaroxaban
@nl
prefLabel
A randomized direct comparison ...... cs of apixaban and rivaroxaban
@ast
A randomized direct comparison ...... cs of apixaban and rivaroxaban
@en
A randomized direct comparison ...... cs of apixaban and rivaroxaban
@nl
P2093
P2860
P356
P1476
A randomized direct comparison ...... cs of apixaban and rivaroxaban
@en
P2093
Charles Frost
Frank LaCreta
Janice Pursley
Jessie Wang
Rebecca A Boyd
Yu Chen Barrett
P2860
P304
P356
10.2147/CPAA.S61131
P407
P577
2014-11-13T00:00:00Z